Invited Speaker

James J. Yoo-Plenary speaker

Wake Forest Institute for Regenerative Medicine (WFIRM)

Update time:2023-12-12 11:13

Dr. Yoo is Professor and Associate Director of the Wake Forest Institute for Regenerative Medicine (WFIRM). Dr. Yoo's research efforts have been directed toward developing tissue engineering technologies and therapeutic approaches for clinical translation. A few notable examples of successful clinical translation include the bladder, urethra, vagina, and muscle cell therapy for incontinence. Dr. Yoo has been a lead scientist in the bioprinting program at WFIRM and has been instrumental in developing skin bioprinting and integrated tissue and organ printing (ITOP) systems for preclinical and clinical applications.

Topic title: Development of Support Technologies that Enhance Clinical Translation


Tissue engineering and regenerative medicine have provided new therapeutic opportunities to the medical field by delivering innovative solutions. The development of non-traditional treatments and cures for unsolvable diseases and conditions has brought hope and excitement to countless individuals globally. Over the years, the field has continued to expand its translational capabilities by integrating new and improved technologies into existing developments, such as bioprinting and bioreactors. Aligned with the goals of tissue engineering, we have followed a strategy that involves the use of biocompatible matrices, either with or without cells. The matrices are either used as a cell delivery vehicle or scaffolds to promote and enhance tissue regeneration. This strategy has been successfully applied to many tissue and organ systems in the clinic. Although this approach has proven to be a viable treatment solution for many tissue and organ conditions, technological improvements that enhance tissue development, manufacturing processes, and delivery method are needed. Furthermore, various scientific and technological challenges inherent to the tissue-building process and implant integration, such as establishing vascularization of volumetric tissue mass, must be overcome to expand the translational capabilities to treat complex tissue systems. This presentation discusses technologies that support and enhance the clinical development and delivery of regenerative medicine products.

Congress has ended
Important Dates
Conference Dates
March 29-31, 2024
Deadline for Submission of Abstract

December 31, 2023

Still open for submission

Notification of Abstract Acceptance

January 15, 2024

January 25, 2024